Phase II study for combination of camrelizumab and apatinib in the second-line treatment of recurrent or metastatic adrenocortical carcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028111

Enrollment

Unknown

Registered

2019-12-12

Start date

2020-01-31

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent or metastatic adrenocortical carcinoma

Interventions

Case series:Camrelizumab plus Apatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed diagnosis of adrenocortical carcinoma; 2. Patients with metastatic or inoperable adrenocortical carcinoma that has progressed, metastasized, or recurred after first line standard treatment (mitotane monotherapy, chemotherapy alone, mitotane combined chemotherapy); 3. Aged >=18 years; 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 5. At least one measurable lesion, according to RECIST 1.1; 6. Major organ functions within 28 days prior to treatment meet the following criteria(14 days without transfusion): HB>=80g/L, ANC>=1.5x10^9/L, PLT >=80x10^9/L; TBIL=60ml/min; INR or PT <=1.5 ULN, APTT <=1.5 ULN (if the patient is receiving anticoagulant therapy, PT and APTT should be within the expected treatment range); 7. Appropriate contraception should be used from the start of treatment to 120 days after the end of treatment; 8. Have signed consent form.

Exclusion criteria

Exclusion criteria: 1. History of prior malignancy, except for cured in situ cervical carcinoma and cured non-melanoma skin cancer; 2. Central nervous system metastasis with symptoms; 3. Active autoimmune disease; 4. Poor control of high blood pressure(SBP>=150mmHg or DBP>=90mmHg); 5. Ischemic cardiovascular events occurred within 1 year prior to the start of treatment; 6. Congestive heart failure of New York Heart Association (NYHA) Class III or IV; 7. Patients are receiving immunosuppressive therapy; 8. Thromboembolic events occurred within 6 months prior to the start of treatment; 9. ECG QT interval >500ms; 10. Patients with symptoms of gastrointestinal bleeding or risk of bleeding; 11. Active infection, or patients are pregnant or breast-feeding.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Secondary

Measure	Time frame
Progression-free Survival;Overall Survival;Adverse Events;	—

Countries

China

Contacts

Public ContactYuchun Zhu

West China Hospital, Sichuan University

mmaalleee@126.com+86 18980605796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026